TBTarah J. Ballinger

Tarah J. Ballinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tarah J. Ballinger has a total of 338 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Contextualizing web-based decision support for endocrine therapy for breast cancer risk reduction: Usability and context insights in a cluster randomized trial

    by Julia D. Caci, Alissa Michel, Peter Zeiger, Anna Vaynrub, Cynthia Law, Vicky Ro, Christina Hijya, Garnet L. Anderson, Kathryn B. Arnold, Sam Dzingle, et al.

    Despite the benefit of endocrine therapy (ET) for breast cancer risk reduction among high-risk women, uptake remains low. In the MiCHOICE trial, we evaluated the effectiveness of a patient decision support tool, RealRisks, compared to standard educational materials in improving informed choice among women with high-risk breast lesions. We found no significant difference in informed choice, but about half initiated ET. To better understand these outcomes, we conducted a qualitative study to explore factors influencing the effectiveness of this tool. We conducted interviews among patients and clinicians assigned to the intervention arm. Interviews were analyzed using the Technology Acceptance Model (TAM). Among 15 enrolled clinicians, 87% were female and 73% were breast surgeons or oncologists. Among 23 enrolled patients, median age was 49.7 years and 70% completed RealRisks. Patients and clinicians found RealRisks’ multimodal presentation of risk to be useful, priming patients for the clinic visit and facilitating more productive conversations regarding ET. However, ease of use was limited by technological barriers and navigation challenges. Patients indicated that RealRisks reinforced clinic conversations rather than changing decisions. Despite positive patient and clinician attitudes toward RealRisks, targeted refinements to the decision aid are needed to translate perceived usefulness into measurable improvements in informed choice. The effectiveness of decision aids may depend not only on their content, but on timing and clinical context. Further studies should evaluate these tools among high-risk women identified in screening mammography or primary care, where impact may be greater.

  • Open Access

    Impact of patient‐reported taxane‐induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG‐ACRIN EAZ171

    by Tarah J. Ballinger, Fengmin Zhao, Guanglong Jiang, Fei Shen, David Cella, John D. Peipert, Kathy D. Miller, Antonio C. Wolff, Angela M. DeMichele, Bryan P. Schneider, et al.

    Background: Black patients with breast cancer experience higher rates of taxane‐induced peripheral neuropathy (TIPN), which may compromise chemotherapy dose delivery and health‐related quality of life (HRQOL). Using the prospective ECOG‐ACRIN EAZ171 trial, the authors examined whether patient‐reported TIPN predicts dose reductions and longer‐term declines in HRQOL and physical function. Methods: EAZ171 enrolled 249 Black patients planned for (neo)adjuvant taxane; 239 with available patient‐reported outcome (PRO) data were analyzed. TIPN was assessed during treatment using the Functional Assessment of Cancer Therapy GOG Neurotoxicity scale (FACT‐GOG/NTx) (4‐item, 11‐item, and single items) and PRO‐Common Terminology Criteria for Adverse Events numbness/tingling and interference. HRQOL (FACT‐G) and physical function (PROMIS PF‐10a) were measured through 12 months. Multivariable mixed‐effects logistic models evaluated associations between TIPN, taxane dose reduction due to neuropathy, and 12‐month HRQOL or physical function decline. Results: All TIPN PROs were associated with dose reduction, with the FACT‐GOG/NTx 4‐item subscale showing the strongest association (odds ratio [OR], 10.8; 95% CI, 4.5–25.9). Twelve‐month PRO data were available for 140 patients (59%). Neuropathy reported during treatment was not associated with reduced HRQOL or physical function at 12 months; however, persistent neuropathy at 12 months was associated with worse HRQOL (OR, 5.05; 95% CI, 1.33–19.17) and physical function (OR, 5.29; 95% CI, 1.57‐17.83). Conclusions: TIPN was common and strongly predicted taxane dose reduction in Black patients. The FACT‐GOG/NTx 4‐item subscale performed best, supporting its use in future trials. Although early TIPN did not predict long‐term functional decline, persistent neuropathy adversely affected HRQOL, underscoring the importance of early identification and supportive care to improve dose delivery and equity in breast cancer outcomes.

  • Open Access

    A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer

    by Kathy D. Miller, Alexandra Thomas, Sandra Althouse, Yong Zang, Erin Conder, Ryan Burgos, Bryan P. Schneider, Tarah Ballinger, Emily Douglas, Katherine Ansley, et al.

    Background: Poly(adenosine diphosphate ribose) polymerase (PARP) is recruited to DNA damage sites along with epigenetic factors such as DNA methyltransferase 1 (DNMT1). Inhibitors of DNMT modulate reactive oxygen species (ROS)‐cyclic adenosine monophosphate (cAMP)/Protein Kinase A signaling and induce a “BRCAness phenotype” that further sensitizes cells to PARPi. In preclinical studies, combined DNMTi + PARPi therapy was effective in both triple‐negative (TNBC) and hormone resistant (HRBC) models with intact BRCA. Methods: The authors conducted a phase 1 study combining the oral DNMTi ASTX727 with the PARPi talazoparib in patients with previously treated TNBC or HRBC. Patients with deleterious mutations of BRCA were excluded. A classical 3+3 design guided dose escalation/de‐escalation, and 28 days constituted each cycle. Serial peripheral blood mononuclear cells (PBMCs) were analyzed for changes in methylation using the Infinium Methylation EPIC BeadChip and LINE1 sequencing. Results: Thirty‐four evaluable patients were enrolled and treated in eight dose cohorts. Myelosuppression was common with grade >3 neutropenia in 42% and grade 3 anemia and thrombocytopenia in 13%. Dose‐limiting toxicity was limited to neutropenia. Efficacy was assessed in 29 patients. There were no objective responses, six patients had stable disease persisting for >4 months in three patients. LINE1 demethylation ranged from ∼2%–10% and immune‐specific CpGs (methylation in immune cells) changed 1%–5% at day 15. Methylation changes were not dose‐dependent. Conclusions: ASTX727 plus talazoparib produces significant myelosuppression without other adverse events. Modest methylation changes in PBMCs were detected. There were no objective responses, but some heavily pretreated patients had stable disease for >4 months despite the attenuated doses.


  • Open Access

    Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)

    by Adrienne G. Waks, Emily L. Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Victoria Attaya, Cari Ryding, Ibrahim Abbass, Anita Fung, Jesse Sussell, et al.

    PURPOSE: The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce this time commitment. This study sought to estimate the difference in time burden between IV and SC administration of trastuzumab and pertuzumab (HP). METHODS: We prospectively enrolled a subcohort of patients participating in the ADEPT trial (ClinicalTrials.gov identifier: NCT04569747 , investigating adjuvant HP plus endocrine therapy for stage I human epidermal growth factor receptor 2–positive breast cancer) to this single-arm crossover time and motion substudy. Patients received two cycles of IV HP followed by two cycles of SC HP. During each cycle, time points in drug preparation and administration were captured. The primary end point was total patient time in the treatment chair. Additional end points included total patient treatment experience time and total pharmacy workflow time. A sample size of 22 patients was estimated to provide 90.7% power with two-sided alpha .05 to detect a difference of 70 minutes in the primary end point by treatment arm (IV v SC). RESULTS: Twenty-two patients were enrolled. The mean total patient time in the treatment chair was 61.8 minutes shorter with SC versus IV HP (22.5 v 84.3 minutes; P < .0001). The mean total patient treatment experience time (incorporating time spent waiting for treatment initiation and time spent in the treatment chair) was 81.8 minutes shorter for SC administration (96 v 177.8 minutes; P < .0001). The pharmacy workflow time was 78.2 minutes shorter for SC versus IV formulation (41 v 119.2 minutes; P < .0001). CONCLUSION: SC administration of HP shortened patient time burden by approximately 1 hour. SC drug administration can facilitate faster workflows for health care professionals and improve patients' breast cancer treatment experience.


  • Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer

    by Catherine E. Mosher, Shieun Lee, Elizabeth L. Addington, Seho Park, Ashley B. Lewson, Stella Snyder, Adam T. Hirsh, Jonathan B. Bricker, Kathy D. Miller, Tarah J. Ballinger, et al.

    PURPOSE: Fatigue is a highly prevalent and disabling symptom for patients with metastatic breast cancer (MBC). Evidence-based interventions for managing fatigue in advanced cancer populations are lacking. This phase II randomized controlled trial tested the effect of acceptance and commitment therapy (ACT) on fatigue interference with functioning in patients with MBC. METHODS: Eligible patients were women with stage IV breast cancer who had moderate to severe fatigue interference. Patients completed a baseline assessment that included self-report measures of fatigue interference with activities, mood, and cognition (primary outcome) and sleep interference with functioning, engagement in daily activities, and quality of life (QOL; secondary outcomes). Then patients were randomly assigned to six weekly telephone-delivered sessions of either ACT (n = 116) or education/support (n = 120). Follow-up assessments occurred at 2 weeks, 3 months, and 6 months postintervention (means, 9.69, 20.51, and 33.59 weeks postbaseline, respectively). RESULTS: Linear mixed model analyses showed that compared with patients in the education/support condition, patients in the ACT condition reported significantly less fatigue interference ( P = .018). These results were significant at 2 weeks and 6 months postintervention. ACT's effect on sleep interference was not statistically significant after the Sidak adjustment for multiple comparisons ( P = .037). ACT patients showed a steady decline in sleep interference, a trend that was not found for education/support patients. Engagement in daily activities and QOL did not significantly differ between study groups, except for functional QOL ( P = .006). Compared with education/support patients, ACT patients showed significantly better functional QOL at 2 weeks and 6 months postintervention. CONCLUSION: Results suggest that a brief, telephone-delivered ACT intervention can reduce fatigue interference with functioning in patients with MBC.


  • Open Access

    Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence

    by Jennifer W Bea, Heather M Ochs-Balcom, Celina I Valencia, Zhao Chen, Robert M Blew, Kimberly E Lind, Bette J Caan, Denise J Roe, Thomas E Rohan, Katherine W Reeves, et al.

    Background: Obesity, classified by body mass index (BMI), is associated with higher postmenopausal breast cancer (BCa) risk. Yet, the associations between abdominal visceral (VAT) and subcutaneous adipose tissue (SAT) with BCa are unclear. Methods: We assessed BCa associations with abdominal VAT and SAT in a prospective cohort of postmenopausal women without a history of cancer and with 27 years follow-up (N = 9950), during which all new cancers were adjudicated. Dual-energy x-ray absorptiometry scans assessed adiposity at baseline, year 3, and year 6. Competing-risks multivariable sub-hazard ratios (SHR), with adjustments for sociodemographic, behavioral, reproductive, and anthropometric characteristics, were estimated for baseline and time-dependent associations between VAT, SAT, and incident BCa. Results: Participants averaged 63.3 ± 7.4 years of age and a BMI of 28.20 ± 5.72 kg/m2 at baseline. The models included 738 incident BCa case patients (N = 593 invasive; N = 145 in situ). Baseline VAT and SAT area were associated with statistically significantly increased BCa risk, by 36% and 19%, respectively. Increasing VAT/SAT ratio was associated with an 8% increase in incident BCa. Time-dependent models produced similar results. VAT and VAT/SAT associated BCa risk was highest for African American/Black women, although not statistically significantly different from other groups. Quartiles (Q) of VAT/SAT were also explored; the SHR for Q4 compared with Q1 was 1.49 (95% CI = 1.18 to 1.87). Conclusion: Higher abdominal VAT and SAT are associated with an increased risk of postmenopausal BCa, and VAT/SAT may provide a distinctive risk estimate. Potential racial and ethnic differences require replication in a larger sample (Women’s Health Initiative; NCT00000611; https://clinicaltrials.gov/study/NCT00000611).


  • Open Access

    Gaps in breast cancer interception efforts at a tertiary cancer center: who are we serving?

    by Rina Yadav, Bailey Johnson, Savannah Phipps, Kali Konstantinopoulos, Manjari Lokender, Jane Ambro, Sandra Althouse, Lisa Hayes, Tarah Balling

    Purpose High-risk breast cancer screening programs (HRSPs) provide personalized interventions that can decrease one’s risk of breast cancer (BC). However, HRSPs introduce inequitable access and utilization by disadvantaged groups. Here, we retrospectively reviewed patients referred to HRSPs to discern race and socioeconomic status differences between those who attended the program versus those who did not. Methods A retrospective analysis was performed on two cohorts presenting for mammography at Indiana academic health centers: 1) patients identified as at increased risk of BC and referred to a HRSP via lay navigators and 2) newly diagnosed BC patients. Individuals attending the HRSP were compared to high-risk patients who declined/did not respond to HRSP invitation, and to newly diagnosed BC individuals. Age, race, insurance status, and neighborhood socioeconomic status were compared between cohorts using Chi-square or Fisher’s exact tests. Results Between 6/2020 and 6/2022, 601 women met criteria for contact by HRSP navigators. Patients accepting appointments were predominately White and privately insured. Black patients more frequently decline appointments compared to White (40.1% v. 29.1%, p = 0.008), and represented a higher proportion of those not attending HRSPs compared to those who did (19.8% v. 10.8%, p = 0.004). Patients diagnosed with BC were more commonly Black (19.4% v. 10.8%, p = 0.003), not privately insured (75.6% v. 84.2%, p = 0.012), and had lower median household incomes (69,611 v.72,656, p = 0.04). Conclusions Significant racial disparities exist amongst patients seen at a tertiary care center’s HRSP. As BC screening/prevention becomes more personalized, efforts should be focused on equitable delivery to minimize inequitable BC outcomes.

  • Open Access

    Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer

    by Tarah J. Ballinger, Mary Lou Smith, Elda Railey, Greg Zimet, Bryan P. Schneider

    The impact of knowledge of circulating tumor DNA (ctDNA) status on patient decisions in high-risk triple-negative breast cancer (TNBC) weighing benefit and toxicity is unknown. Here, 286 women with a history of non-metastatic breast cancer who had received chemotherapy completed a survey mimicking scenarios of residual TNBC after chemotherapy and unknown, negative, or positive ctDNA status to determine the shift in the decision to receive adjuvant therapy. Participants were then presented scenarios mimicking possible post-neoadjuvant therapies and rated acceptability. A general linear model with repeated measures determined contributions of risk reduction and toxicity. When the hypothetical risk of recurrence mimicked ctDNA negativity, significantly less participants were accepting of adjuvant capecitabine versus no therapy. When presented with ctDNA positivity and increased recurrence risk, the degree of benefit impacted acceptability more than the toxicity profile. As genomic technology advances and ctDNA assays become commercially available, it is imperative to understand the impact on patient decision-making.


  • Open Access

    Exercise as part of survivorship care in metastatic breast cancer: protocol for the randomized EMBody trial

    by Martha A. Cancilla, Donya Nemati, Danielle Halsey, Niraj Shah, Melissa Sherman, Nicholas Kelly, Pengyue Zhang, Nada Kassem, Navin Kaushal, Kelly Shanahan, et al.

    Exercise is associated with improved survival, physical functioning, treatment tolerability, and quality of life in early-stage breast cancer. These same endpoints matter in metastatic breast cancer (MBC). Prior trials in MBC have found exercise to be not feasible or of limited benefit, possibly due to inclusion of patients with heterogeneous disease trajectories. Patients with MBC have variable disease trajectories and supportive care needs; those with indolent MBC have longer life expectancy, lower symptom burden and distinct priorities, and are well-positioned to participate in and benefit from an exercise program. The EMBody trial aims to determine the impact of a multimodal exercise intervention on cardiorespiratory fitness, physical function, body composition, and patient-reported outcomes, specifically in patients with stable, indolent MBC. Eligible patients have MBC with no evidence of disease progression on current therapy in the prior 12 months and cannot be receiving cytotoxic chemotherapy. The trial aims to enroll 100 patients, randomized 1:1 to the exercise intervention versus usual care, stratified by baseline function. The virtually-delivered exercise intervention arm achieves moderate intensity exercise with exercise physiologists 3 days/week for 16 weeks. The 60-minute sessions include aerobic, resistance, balance and stretching exercises. The exercise arm receives informational sessions on the role of exercise in cancer and principles of habit and self-efficacy. The primary endpoint is 16 week change in fitness on a ramp treadmill test between the exercise and control arms. Secondary endpoints include change in a physical function, muscle mass assessed by CT scans, and PROs of fatigue and quality of life. Exploratory analysis includes behavioral modifiers of exercise adherence and effectiveness and serologic measures of inflammatory, metabolic, and immune pathway biomarkers. The EMBody trial evaluates exercise in a unique patient population with indolent, non-progressive MBC. Patients living with MBC experience similar symptom burden to those undergoing therapy for early-stage disease and the benefits achieved with exercise could be similarly impactful. This trial will contribute evidence to support expansion of exercise recommendations, among other survivorship care efforts, to those living with metastatic disease. Clinical trial information: NCT05468034. NCT05468034. Date of registration: 7/12/2022.


  • ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

    by Bryan P. Schneider, Fengmin Zhao, Tarah J. Ballinger, Sofia F. Garcia, Fei Shen, Shamsuddin Virani, David Cella, Casey Bales, Guanglong Jiang, Lisa Hayes, et al.

    PURPOSE: Black women experience higher rates of taxane-induced peripheral neuropathy (TIPN) compared with White women when receiving adjuvant once weekly paclitaxel for early-stage breast cancer, leading to more dose reductions and higher recurrence rates. EAZ171 aimed to prospectively validate germline predictors of TIPN and compare rates of TIPN and dose reductions in Black women receiving (neo)adjuvant once weekly paclitaxel and once every 3 weeks docetaxel for early-stage breast cancer. METHODS: Women with early-stage breast cancer who self-identified as Black and had intended to receive (neo)adjuvant once weekly paclitaxel or once every 3 weeks docetaxel were eligible, with planned accrual to 120 patients in each arm. Genotyping was performed to determine germline neuropathy risk. Grade 2-4 TIPN by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 was compared between high- versus low-risk genotypes and between once weekly paclitaxel versus once every 3 weeks docetaxel within 1 year. Patient-rated TIPN and patient-reported outcomes were compared using patient-reported outcome (PRO)–CTCAE and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity. RESULTS: Two hundred and forty of 249 enrolled patients had genotype data, and 91 of 117 (77.8%) receiving once weekly paclitaxel and 87 of 118 (73.7%) receiving once every 3 weeks docetaxel were classified as high-risk. Physician-reported grade 2-4 TIPN was not significantly different in high- versus low-risk genotype groups with once weekly paclitaxel (47% v 35%; P = .27) or with once every 3 weeks docetaxel (28% v 19%; P = .47). Grade 2-4 TIPN was significantly higher in the once weekly paclitaxel versus once every 3 weeks docetaxel arm by both physician-rated CTCAE (45% v 29%; P = .02) and PRO-CTCAE (40% v 24%; P = .03). Patients receiving once weekly paclitaxel required more dose reductions because of TIPN (28% v 9%; P < .001) or any cause (39% v 25%; P = .02). CONCLUSION: Germline variation did not predict risk of TIPN in Black women receiving (neo)adjuvant once weekly paclitaxel or once every 3 weeks docetaxel. Once weekly paclitaxel was associated with significantly more grade 2-4 TIPN and required more dose reductions than once every 3 weeks docetaxel.